AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31212162
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of oral contraceptives
Trial: 18486235
Drug: Venlafaxine 37.5-375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine 37.5-375 mg daily
Trial: 18486235
Drug: Lithium 300-2100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium 300-2100 mg daily
Trial: 17286342
Drug: Broad-spectrum treatment
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broad-spectrum treatment (BST) with naltrexone
Trial: 17286342
Drug: Motivational-enhancement therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational-enhancement therapy (MET) with naltrexone
Trial: 14712408
Drug: Protocol A
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol A (single injection of Gd‐BOPTA)
Trial: 14712408
Drug: Protocol B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol B (two injections of Gd‐BOPTA)
Trial: 10749620
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) treatment (0.3 U/kg/day)
Trial: 30716797
Drug: Interval between
RxNorm normalized name: CYCLIZED P12 (PEPTIDE BOND BETWEEN THE CARBOXY AND AMINO-TERMINAL ENDS OF THE LINEAR PEPTIDE PSHISKYILRWRPK)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interval between onset of symptoms and therapy
Trial: 9839777
Drug: Teril 600
RxNorm normalized name: Teril CR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teril 600 CR tablet
Trial: 9839777
Drug: Timonil 600
RxNorm normalized name: Timonil Retard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timonil 600 Retard tablet
Trial: 7862232
Drug: Typical treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Typical treatment + ganglioside GM1 (100 mg daily for 30 days, i.v. for first 5 days, then i.m.)
Trial: 7862232
Drug: Typical treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Typical treatment + ganglioside GM1
Trial: 28940312
Drug: 100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg LSD administered orally
Trial: 21633025
Drug: Oral sitamaquine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sitamaquine, 2 mg/kg/day, once a day for 21 days
Trial: 21633025
Drug: Intravenous amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous amphotericin B (AmB), 1 mg/kg every other day for 30 days
Trial: 16923135
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg zinc sulfate three times daily
Trial: 16923135
Drug: Identical placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo tablet three times daily
Trial: 16923135
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg zinc sulfate three times daily (after crossover)
Trial: 16923135
Drug: Identical placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo tablet three times daily (after crossover)
Trial: 10857970
Drug: Troglitazone (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone (600 mg/day) for 12 weeks
Trial: 1440306
Drug: Nitrendipine 40
RxNorm normalized name: nitrendipine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine 40 mg/day
Trial: 1440306
Drug: Nitrendipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (20 mg once or twice a day)
Trial: 1440306
Drug: Nitrendipine 20
RxNorm normalized name: nitrendipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine 20 mg twice a day
Trial: 26762911
Drug: BFD (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BFD (standard dose)
Trial: 26762911
Drug: BFD-LD (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BFD-LD (low dose)
Trial: 22999589
Drug: Bronchoscopic argon
RxNorm normalized name: argon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bronchoscopic argon plasma coagulation plus routine antituberculosis chemotherapy
Trial: 22999589
Drug: Routine antituberculosis
RxNorm normalized name: Mycobacterium tuberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine antituberculosis chemotherapy
Trial: 18254486
Drug: Azelastine nasal
RxNorm normalized name: azelastine nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine nasal spray, 2 sprays per nostril twice daily
Trial: 18254486
Drug: Fluticasone nasal
RxNorm normalized name: fluticasone nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone nasal spray, 2 sprays per nostril once daily
Trial: 18254486
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of azelastine nasal spray and fluticasone nasal spray
Trial: 17006062
Drug: Morphine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine administration postoperatively
Trial: 8867642
Drug: 3% diclofenac/2.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% diclofenac/2.5% sodium hyaluronate topical gel, applied 4 times daily for 2 weeks
Trial: 8867642
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel lacking the active substance
Trial: 29584458
Drug: Cilnidipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilnidipine (10 mg/day) for 12 weeks
Trial: 16480350
Drug: 10 mg.kg(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg.kg(‐1) methylprednisolone
Trial: 11963730
Drug: Heparin during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin during acute therapy of AMI
Trial: 11963730
Drug: No heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No heparin during acute therapy of AMI
Trial: 11963730
Drug: Heparin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin with fibrinolysis
Trial: 11963730
Drug: No heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No heparin with fibrinolysis
Trial: 7656462
Drug: Non-insulin-dependent diabetes
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-insulin-dependent diabetes mellitus
Trial: 2566219
Drug: Histamine injection
DrugBank: Histamine (DB05381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Histamine injection (increasing concentration)
Trial: 2566219
Drug: Histamine injection
DrugBank: Histamine (DB05381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Histamine injection (decreasing concentration)
Trial: 17503182
Drug: Imipramine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (50 mg)
Trial: 827779
Drug: Nomifensine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nomifensine (50 mg)
Trial: 26810496
Drug: Adjustable, custom-made
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjustable, custom-made oral appliance (Narval®) without elastic bands
Trial: 26810496
Drug: Adjustable, custom-made
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjustable, custom-made oral appliance (Narval®) with elastic bands
Trial: 25209323
Drug: Action 3:30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Action 3:30 intervention (40 one-hour sessions, delivered twice a week by teaching assistants)
Trial: 17018708
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (CHOP-21, CHOP-14)
Trial: 12391522
Drug: Face mask
RxNorm normalized name: CVS Face Masks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face mask with O(2) flow of 15 l/min
Trial: 7597662
Drug: Phosphoramidon (10(‐5)
RxNorm normalized name: phosphoramidic acid
DrugBank: Phosphoramidon (DB02557)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphoramidon (10(‐5) M, 3 ml)
Trial: 2205358
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (MA) 480 mg/day
Trial: 31958907
Drug: Metformin (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1,000 mg/day)
Trial: 30311850
Drug: Internet-facilitated cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-facilitated cognitive behavioral therapy (Mom-Net)
Trial: 16804289
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with OSAS before CPAP treatment
Trial: 3548637
Drug: Clomipramine hydrochloride
RxNorm normalized name: Clomipramine Hydrochloride
DrugBank: Clomipramine (DB01242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomipramine hydrochloride (134 +/- 33 mg/d)
Trial: 28864691
Drug: RDN using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RDN using 5F saline‐irrigated radiofrequency ablation (RFA) plus antihypertensive medication
Trial: 7477146
Drug: Antihypertensive medication
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive medication alone
Trial: 11023499
Drug: High levels
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High levels of MRD at the end of the induction phase (> or = 1%) or at week 14 of continuation therapy (> or = 0.1%)
Trial: 8612107
Drug: Ibuprofen (1800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (1800 mg per day)
Trial: 6096282
Drug: Glucomannan fiber
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucomannan fiber (1-g doses, two 500 mg capsules with 8 oz water, 1 h prior to each meal)
Trial: 29454678
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg CoQ10 daily for 24 weeks
Trial: 23293082
Drug: Rituximab +
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab + Dexamethasone (40 mg/day for 4 days and 375 mg/m² weekly for 4 weeks)
Trial: 21624649
Drug: Oral methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral methylprednisolone (15 days with tapering schedule) plus oral amoxicillin/clavulanate (AMX/C)
Trial: 21624649
Drug: Oral amoxicillin/clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral amoxicillin/clavulanate (AMX/C) plus placebo
Trial: 16456411
Drug: Prepackaged diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prepackaged diet kit plus magnesium citrate/bisacodyl laxative (group 1)
Trial: 16456411
Drug: Clear liquids
RxNorm normalized name: salicylic acid Medicated Liquid Soap [clear days ahead]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clear liquids and sodium phosphate solution (group 2)
Trial: 11816867
Drug: Mirtazapine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine (40 weeks of double-blind continuation-phase therapy)
Trial: 11816867
Drug: Placebo (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (40 weeks of double-blind continuation-phase therapy)
Trial: 3630598
Drug: Heating humidifier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heating humidifier of inhaled gases
Trial: 27594150
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy combined with treatment for ameliorating the PE symptom (oral dapoxetine on-demand and ejaculation control exercise)
Trial: 27594150
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (oral administration of antibiotics, α-receptor blocker, and proprietary Chinese medicine)
Trial: 23868273
Drug: Minocycline 100
RxNorm normalized name: minocycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline 100 mg intravenously, administered 12 hourly for a total of 5 doses
Trial: 20082104
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (Aluminum gallium arsenide laser, 785 nm, 3 J/cm², 70 mW)
Trial: 12816140
Drug: Atraumatic restorative
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atraumatic restorative treatment (ART) restorations
Trial: 11388500
Drug: Nitroderivative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroderivative therapy
Trial: 9356879
Drug: Cimetidine 300
RxNorm normalized name: cimetidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 300 mg i.v. bolus followed by 300 mg i.v. every 6 hr during hospitalization
Trial: 9356879
Drug: Heater probe
RxNorm normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heater probe thermocoagulation + cimetidine 300 mg i.v. bolus followed by 300 mg i.v. every 6 hr during hospitalization
Trial: 9356879
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg i.v. bolus followed by 40 mg i.v. daily for two days
Trial: 9356879
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg i.v. bolus followed by 40 mg i.v. every 12 h for two days
Trial: 8146390
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of mefloquine every month
Trial: 8146390
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg of mefloquine every two weeks
Trial: 8146390
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg sulphadoxine + 25 mg pyrimethamine (Fansidar) a week
Trial: 3524176
Drug: Combined probucol
RxNorm normalized name: Probucol
DrugBank: Probucol (DB01599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined probucol (1 g/day) and colestipol (20 g/day)
Trial: 3524176
Drug: Modified probucol-colestipol
RxNorm normalized name: Probucol
DrugBank: Probucol (DB01599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Modified probucol-colestipol therapy (half-dose of colestipol)
Trial: 3524176
Drug: Combined probucol-colestipol
RxNorm normalized name: Probucol
DrugBank: Probucol (DB01599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined probucol-colestipol therapy after 1 and 3 years
Trial: 3524176
Drug: Single-drug administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-drug administration of probucol or colestipol
Trial: 30182113
Drug: Lactoferrin (LF)
DrugBank: Lactoferrin (DB16555)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactoferrin (LF) supplementation, 3 tablets per day (250 mg per tablet) for 30 days
Trial: 26813357
Drug: ISA101 vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISA101 vaccination with 5% imiquimod at the vaccine site
Trial: 24840349
Drug: Early detection
RxNorm normalized name: Leader Early Detection Pregnancy Test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early detection and treatment by community health workers using rapid diagnostic technology
Trial: 24840349
Drug: Early detection
RxNorm normalized name: Leader Early Detection Pregnancy Test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early detection and treatment plus larviciding
Trial: 23835590
Drug: Intrathecal gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal gabapentin 0 mg/day (placebo)
Trial: 23835590
Drug: Intrathecal gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal gabapentin 1 mg/day
Trial: 23835590
Drug: Intrathecal gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal gabapentin 6 mg/day
Trial: 23835590
Drug: Intrathecal gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal gabapentin 30 mg/day
Trial: 23835590
Drug: Intrathecal gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal gabapentin (all doses)
Trial: 20455960
Drug: Allogenic platelet
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogenic platelet gel
Trial: 12536327
Drug: Endoscopic fibrin
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic fibrin glue injection
Trial: 10645753
Drug: 7 mg
RxNorm normalized name: pectin 7 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 mg tacrolimus
Trial: 10645753
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg tacrolimus
Trial: 8876707
Drug: Combined androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined androgen blockade (CAB) with zoladex 3.6 mg injection subcutaneous depot monthly and flutamide 250 mg orally three times per day for 2 months, followed by CAB with concurrent XRT (65-70 Gy) for 7-8 weeks
Trial: 8876707
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further treatment (Z- group)
Trial: 1543618
Drug: Temazepam elixir
RxNorm normalized name: Temazepam
DrugBank: Temazepam acetate (DB14671)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Temazepam elixir
Trial: 3892975
Drug: Metronidazole (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (9 doses)
Trial: 25224018
Drug: PNHA (topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PNHA (topical gel application two times a week for a total of 6 weeks)
Trial: 25224018
Drug: HA (topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HA (topical application)
Trial: 24708617
Drug: Minimal contact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal contact web-guided Cognitive Behavioral Therapy (CBT) intervention
Trial: 16046715
Drug: High protein,
RxNorm normalized name: Ensure High Protein, Banana, Instant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein, reduced carbohydrates diet (1.6 g/(kg . d)) with supervised exercise (5 d/wk walking and 2 d/wk resistance training)
Trial: 16046715
Drug: Low protein,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low protein, high carbohydrates diet (0.8 g/(kg . d)) with supervised exercise (5 d/wk walking and 2 d/wk resistance training)
Trial: 16046715
Drug: High protein,
RxNorm normalized name: Ensure High Protein, Banana, Instant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein, reduced carbohydrates diet (1.6 g/(kg . d)) with lifestyle activity (control)
Trial: 16046715
Drug: Low protein,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low protein, high carbohydrates diet (0.8 g/(kg . d)) with lifestyle activity (control)
Trial: 1712803
Drug: Allergen challenge
RxNorm normalized name: catfish allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergen challenge (single dose sprayed into one side of the nose)
Trial: 6227877
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ipratropium bromide (40 micrograms/puff) and fenoterol (100 micrograms/puff)
Trial: 23569986
Drug: Cisplatin chemotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin chemotherapy (40-50 mg/day)
Trial: 19951955
Drug: Experimental adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental adjuvant treatments
Trial: 19951955
Drug: New treatments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New treatments for metastatic disease
Trial: 17330176
Drug: Cholinesterase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholinesterase inhibitors (ChEI)
Trial: 15857723
Drug: Matrix Model
RxNorm normalized name: Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matrix Model (manualized treatment)
Trial: 12569793
Drug: Chongcao shenkang
RxNorm normalized name: CAMPHOR (SYNTHETIC) 4.28 mg in 100 mg / MENTHOL 2.84 mg in 100 mg / METHYL SALICYLATE 1.4 mg in 100 mg TRANSDERMAL PLASTER [Shennong Analgesic Plaster]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chongcao shenkang capsules 2.7 grams tid
Trial: 12569793
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (combined therapy with balanced salt solution and ribavirin)
Trial: 7475162
Drug: Recombinant aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recombinant aprotinin (dosage level 1: 2 mg/kg bolus, 1 mg/kg in oxygenator prime, 0.5 mg/kg/hr infusion)
Trial: 7475162
Drug: Recombinant aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recombinant aprotinin (dosage level 2: doubled doses)
Trial: 7475162
Drug: Recombinant aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recombinant aprotinin (dosage level 1)
Trial: 7475162
Drug: Recombinant aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recombinant aprotinin (dosage level 2)
Trial: 7002430
Drug: Bendroflumethiazide 10
RxNorm normalized name: bendroflumethiazide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendroflumethiazide 10 mg daily for 3 days